Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engaging leadership and nurses' mental health in German acute care hospitals: the mediating role of job resources.

BMC nursing·2026
Same author

[Formation of disease- and needs-related homogeneous groups of insured persons - PopGrouper 1.0].

Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))·2026
Same author

Regional variation in healthcare utilization among patients with depression in Germany: a multilevel analysis with PopGrouper-based multimorbidity adjustment.

Research in health services & regions·2026
Same author

Cost-effectiveness of prehabilitation for elderly (pre-)frail patients prior to elective surgery compared to standard care - an economic evaluation from a societal perspective.

BMC medicine·2026
Same author

Metal concentration in biological samples of shipyard welders: a scoping review.

International journal of hygiene and environmental health·2026
Same author

West African Policy Dialogue-impulse for better data: progress towards better analytics and better decisions.

BMC proceedings·2026
Same journal

Variability in the prescription of drugs with uncertain effectiveness. The case of SYSADOA in the Basque Country.

GMS health technology assessment·2019
Same journal

Q-SEA - a tool for quality assessment of ethics analyses conducted as part of health technology assessments.

GMS health technology assessment·2017
Same journal

Effects of continuous and intermittent renal replacement therapies among adult patients with acute kidney injury.

GMS health technology assessment·2017
Same journal

Telemedicine: The legal framework (or the lack of it) in Europe.

GMS health technology assessment·2016
Same journal

Complex health care interventions: Characteristics relevant for ethical analysis in health technology assessment.

GMS health technology assessment·2016
Same journal

Electronic health records: Is it a risk worth taking in healthcare delivery?

GMS health technology assessment·2015
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Ventricular assist devices for heart failure.

Lucia Angermayr1, Marcial Velasco Garrido, Reinhard Busse

  • 1Technische Universität Berlin, Berlin, Deutschland.

GMS Health Technology Assessment
|February 4, 2011
PubMed
Summary
This summary is machine-generated.

Left ventricular assist devices (LVADs) improve survival and quality of life for heart failure patients compared to medical therapy. However, LVADs have significant risks and high costs, requiring further technological development.

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Experiment Videos

Last Updated: Jun 4, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Area of Science:

  • Cardiology
  • Medical Technology
  • Health Economics

Background:

  • Heart failure is a significant cause of mortality and disability globally.
  • Ventricular assist devices offer therapeutic options for patients unresponsive to medical treatment.
  • Left ventricular assist devices (LVADs) serve as bridge to transplant, bridge to recovery, or destination therapy.

Purpose of the Study:

  • To evaluate the clinical effectiveness of LVADs.
  • To assess the psychological, social, and economic aspects of LVADs.
  • To present current evidence on LVADs in heart failure management.

Main Methods:

  • Systematic literature review across EMBASE, MEDLINE, and Cochrane Library.
  • Assessment of included studies by two independent reviewers.
  • Narrative synthesis of findings and a survey of hospitals utilizing LVAD technology.

Main Results:

  • LVADs as bridge to transplant demonstrated improved survival and quality of life versus medical therapy.
  • Adverse events, including serious complications, were frequent and often fatal.
  • Significant psychological and psychiatric issues were observed in LVAD patients.

Conclusions:

  • LVADs are clinically effective but associated with a high rate of serious complications.
  • The high cost of LVADs necessitates a cost-effectiveness analysis for Germany.
  • Further technological advancements are needed to optimize LVADs and reduce reliance on heart transplantation.